BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
1.820
+0.250 (15.92%)
Aug 17, 2026, 4:00 PM EDT - Market closed
BioNexus Gene Lab Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.23 | 2.38 | 1.58 | 2.62 | 0.61 | 0.58 |
Short-Term Investments | 2.29 | 1.66 | 2.79 | 3.31 | 1.51 | 1.55 |
Cash & Short-Term Investments | 3.52 | 4.04 | 4.38 | 5.93 | 2.12 | 2.12 |
Cash Growth | 15.13% | -7.71% | -26.17% | 179.84% | -0.24% | -23.81% |
Accounts Receivable | 0.02 | 0.51 | 1.38 | 0.8 | 2.87 | 3.36 |
Other Receivables | 0.17 | 0.14 | 0.29 | 0.18 | 0.06 | 0.08 |
Receivables | 0.19 | 0.65 | 1.66 | 0.98 | 2.93 | 3.44 |
Inventory | 0.65 | 0.68 | 1.39 | 1.14 | 0.98 | 1.52 |
Other Current Assets | 0.58 | 0.08 | - | - | - | 0.07 |
Total Current Assets | 4.94 | 5.45 | 7.43 | 8.05 | 6.02 | 7.15 |
Property, Plant & Equipment | 1.76 | 1.78 | 1.74 | 1.65 | 1.57 | 1.68 |
Long-Term Investments | 2.03 | 2.03 | 1.27 | 1.7 | 1.15 | 0.75 |
Total Assets | 8.73 | 9.25 | 10.43 | 11.4 | 8.74 | 9.57 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.01 | 0 | 1.5 | 1.4 | 1.86 | 2.01 |
Short-Term Debt | 0.12 | 0.05 | 0.02 | 0.01 | - | - |
Current Portion of Leases | 0.06 | 0.06 | 0.05 | 0.03 | 0.02 | 0.04 |
Current Income Taxes Payable | - | - | - | - | - | 0.1 |
Current Unearned Revenue | - | - | - | - | - | 0.08 |
Other Current Liabilities | 0.62 | 0.41 | 0.38 | 0.18 | 0.13 | 0.1 |
Total Current Liabilities | 0.81 | 0.52 | 1.95 | 1.63 | 2 | 2.33 |
Long-Term Leases | 0.14 | 0.12 | 0.16 | 0.1 | 0.04 | 0.04 |
Long-Term Deferred Tax Liabilities | - | - | - | 0.01 | 0.03 | 0.03 |
Total Liabilities | 0.95 | 0.64 | 2.11 | 1.74 | 2.08 | 2.39 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 20.17 | 20.17 | 17.33 | 17.19 | 10.93 | 10.78 |
Retained Earnings | -7.26 | -6.43 | -3.44 | -1.84 | 1.16 | 1.51 |
Comprehensive Income & Other | -5.14 | -5.13 | -5.57 | -5.69 | -5.42 | -5.11 |
Shareholders' Equity | 7.78 | 8.61 | 8.32 | 9.66 | 6.67 | 7.18 |
Total Liabilities & Equity | 8.73 | 9.25 | 10.43 | 11.4 | 8.74 | 9.57 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.32 | 0.23 | 0.23 | 0.15 | 0.06 | 0.08 |
Net Cash (Debt) | 3.2 | 3.81 | 4.15 | 5.78 | 2.06 | 2.05 |
Net Cash Growth | 12.38% | -8.09% | -28.24% | 180.43% | 0.74% | -23.17% |
Net Cash Per Share | 1.48 | 2.05 | 2.33 | 3.64 | 1.43 | 1.43 |
Filing Date Shares Outstanding | 2.42 | 2.42 | 1.8 | 1.77 | 1.45 | 1.43 |
Total Common Shares Outstanding | 2.42 | 2.42 | 1.8 | 1.77 | 1.45 | 1.43 |
Working Capital | 4.13 | 4.93 | 5.48 | 6.42 | 4.02 | 4.82 |
Book Value Per Share | 3.22 | 3.56 | 4.63 | 5.47 | 4.60 | 5.03 |
Tangible Book Value | 7.78 | 8.61 | 8.32 | 9.66 | 6.67 | 7.18 |
Tangible Book Value Per Share | 3.22 | 3.56 | 4.63 | 5.47 | 4.60 | 5.03 |
Land | - | 1.51 | 1.51 | 1.51 | 1.51 | 1.51 |
Machinery | - | 0.91 | 0.88 | 0.68 | 0.65 | 0.59 |
Construction In Progress | - | - | - | 0.11 | - | - |